当前位置：
X-MOL 学术
›
Am. J. Clin. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer.
American Journal of Clinical Oncology ( IF 1.6 ) Pub Date : 2021-07-26 , DOI: 10.1097/coc.0000000000000854 William T Arscott 1, 2 , Kevin T Nead 1, 3 , Adham Bear 4 , Sriram Venigalla 1 , Jacob Shabason 1 , John N Lukens 1 , John P Plastaras 1 , Andrzej Wojcieszynski 1 , James Metz 1 , Mark O'Hara 4 , Kim A Reiss 4 , Ursina Teitelbaum 4 , Arturo Loaiza-Bonilla 4, 5 , Jeffrey Drebin 6, 7 , Major K Lee 6 , Stuti G Shroff 8 , Edgar Ben-Josef 1
American Journal of Clinical Oncology ( IF 1.6 ) Pub Date : 2021-07-26 , DOI: 10.1097/coc.0000000000000854 William T Arscott 1, 2 , Kevin T Nead 1, 3 , Adham Bear 4 , Sriram Venigalla 1 , Jacob Shabason 1 , John N Lukens 1 , John P Plastaras 1 , Andrzej Wojcieszynski 1 , James Metz 1 , Mark O'Hara 4 , Kim A Reiss 4 , Ursina Teitelbaum 4 , Arturo Loaiza-Bonilla 4, 5 , Jeffrey Drebin 6, 7 , Major K Lee 6 , Stuti G Shroff 8 , Edgar Ben-Josef 1
Affiliation
This study evaluates the toxicity and tumor response with concurrent nab-paclitaxel chemoradiotherapy (CRT) compared with standard (5-fluorouracil or gemcitabine) CRT.
中文翻译：
同步白蛋白结合型紫杉醇和放射治疗：用于边缘性可切除或不可切除胰腺癌的新型放射增敏。
本研究评估了同步白蛋白结合型紫杉醇放化疗 (CRT) 与标准（5-氟尿嘧啶或吉西他滨）CRT 的毒性和肿瘤反应。
更新日期：2021-07-26
中文翻译：
同步白蛋白结合型紫杉醇和放射治疗：用于边缘性可切除或不可切除胰腺癌的新型放射增敏。
本研究评估了同步白蛋白结合型紫杉醇放化疗 (CRT) 与标准（5-氟尿嘧啶或吉西他滨）CRT 的毒性和肿瘤反应。
京公网安备 11010802027423号